# Autologous CD4+ antigen-specific T-cell clones in metastatic melanoma (Fred Hutchinson phase 1)

Source: https://onco.cc/trials/nct00045357/  
OnCo record `nct00045357` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Seattle safety trial of helper T cells grown from patients' own blood to recognise melanoma. It ran from 2001 to 2008 and the registry posts no results.

## Summary

The registry describes a phase I safety study of cellular adoptive immunotherapy using autologous CD4+ antigen-specific T-cell clones in metastatic melanoma, started in November 2001 and completed in August 2008, with an estimated enrolment of 18 (ClinicalTrials.gov NCT00045357). Cassian Yee is listed as study chair; the sponsor is Fred Hutchinson Cancer Center with the National Cancer Institute as collaborator (ClinicalTrials.gov NCT00045357). No results are posted.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-05
- Registry id: NCT00045357
- Phase: 1
- Setting: Metastatic melanoma: autologous CD4+ antigen-specific T-cell clones
- Sponsor: Fred Hutchinson Cancer Center, with the National Cancer Institute
- Result: No results posted on ClinicalTrials.gov.

## Sources

- ClinicalTrials.gov NCT00045357: https://clinicaltrials.gov/study/NCT00045357

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- institutions: [Fred Hutchinson Cancer Center](https://onco.cc/institutions/fred-hutch/), [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/)
- terms: [Endogenous T-cell therapy](https://onco.cc/terms/endogenous-t-cell-therapy/)
- people: [Cassian Yee](https://onco.cc/people/cassian-yee/)

---
JSON: https://onco.cc/api/v1/entities/nct00045357.json